Table 2.

COVID-19 Vaccine efficacy for infection and substantial symptomatic disease

A. COVID-19 VE for infection
Variable	Person-days	Positive cases	Incidence rate per 1000 person-days	Crude VE	Adjusted VE
mRNA1273 controls (N = 129)	7577	61	8.05	-ref-	-ref-
mRNA1273 (N = 115)	8029	45	5.6	30.4%	24.6% (−10.8–49.1%)
BNT162b2 controls (N = 297)	9669	69	7.14	-ref-	-ref-
BNT162b2 (N = 150)	10,697	66	6.17	13.6%	2.8% (−37.7–31.5%)

B. COVID-19 VE for substantial symptomatic disease
mRNA1273 controls (N = 126)	7377	20	2.71	-ref-	-ref-
mRNA1273 (N = 115)	8029	2	0.25	90.8%	89.3% (63.2–98.3%)
BNT162b2 controls (N = 291)	9395	35	3.73	-ref-	-ref-
BNT162b2 (N = 147)	10,541	10	0.95	74.5%	71% (42.63–86.63%)

Vaccine efficacy is calculated as 1-IRR.